Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ICML 2023 | Interim analysis of anbal-cel for R/R DLBCL

Won-Seog Kim • 16 Jun 2023
ICML 2023
Diffuse Large B-Cell Lymphoma Lymphoma Non-Hodgkin Lymphoma Anbalcabtagene autoleucel CAR-T

Won-Seog Kim, MD, PhD, Sungkyunkwan University School of Medicine, Seoul, South Korea, discusses a Phase I/II study evaluating anbalcabtagene autoleucel (anbal-cel), an anti-CD19 CAR-T therapy with dual silencing of PD-1 and TIGIT, for patients with relapsed/refractory diffuse large B-cell lymphoma (R/R DLBCL; NCT04836507). Prof. Kim shares the encouraging efficacy and safety data from the interim analysis of the trial. This interview took place at the 17th International Conference on Malignant Lymphoma (ICML), held in Lugano, Switzerland.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

More from Won-Seog Kim

1:11
DISTINKT trial analysis: efficacy and safety of IMC-001 for R/R ENKTL
Won-Seog Kim • 16 Jun 2023
1:35
REDIRECT results: AFM13 in patients with CD30+ R/R PTCL
Won-Seog Kim • 16 Jun 2023
1:07
Golidocitinib in R/R PTCL: analysis of the JACKPOT8 trial
Won-Seog Kim • 16 Jun 2023
1:57
Standard of care of CAR-T therapies for B-cell malignancies
Won-Seog Kim • 24 Nov 2022

Related Videos

3:32
Improving CAR-T therapy for ALL & lymphoma: allogeneic products & reducing CRS/ICANS
Sridhar Chaganti • 16 Apr 2024
2:11
The role of CAR-T therapy for lymphoma in 2024: expert session highlights
Sridhar Chaganti • 16 Apr 2024
1:32
Promising novel immunotherapeutic approaches in lymphoma
Gloria Iacoboni • 15 Apr 2024
3:03
AlloSCT outcomes after immunotherapy vs chemotherapy in patients with R/R NHL: a retrospective study
Jacopo Mariotti • 15 Apr 2024
The content of VJHemOnc is intended for healthcare professionals